Biomarkers for the Diagnosis of Transient Ischemic Attack (MAESTRO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02799511|
Recruitment Status : Recruiting
First Posted : June 15, 2016
Last Update Posted : August 17, 2018
A transient ischemic attack (TIA) should be considered an emergency prevention opportunity in order to avoid recurrence as cerebral infarction (CI) serious (fatal or disabling). Indeed, about 20% of patients who have IC had in previous days or weeks, a TIA, which can be defined as a brief episode of cerebral dysfunction (or eye) do not result in permanent brain damage and thus no sequelae. Moreover, about 20% of ischemic events observed in practice are AIT. Despite the progress achieved in the treatment in the acute phase of an IC, prevention remains the most effective way to fight against this disease. This prevention can be put in place before the occurrence of a first IC, or after a first IC, especially when minor as a TIA.
However, the diagnosis of TIA remains particularly difficult and it is necessary now to identify new tools for the diagnosis of transient ischemic attack. Our study focused on the identification of one or more molecules (called biological markers or biomarkers) present in the bloodstream of patients, which will serve to facilitate the differential diagnosis of patients with TIA.
|Condition or disease||Intervention/treatment||Phase|
|Cerebrovascular Disorders Ischemic Attack, Transient||Biological: protein expression||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Biomarkers for the Diagnosis of Transient Ischemic Attack|
|Study Start Date :||March 2015|
|Estimated Primary Completion Date :||September 2018|
|Estimated Study Completion Date :||September 2019|
Biological: protein expression
Differential protein expression between the period of acute cerebral ischemia and the control period
- change in proteomic analysis from MPs or from plasma. [ Time Frame: baseline and 72h after TAI and 90 days after TAI ]Identify one or more markers of transient ischemic attack by a proteomic analysis from MPs or from plasma.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02799511
|Contact: COGEZ Julien, MD||+33 2 31 06 46 firstname.lastname@example.org|
|Caen University Hospital||Recruiting|
|Caen, France, 14033|
|Contact: Cogez Julien, MD|